Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

May 16, 2023

SELL
$25.5 - $41.42 $249,900 - $405,916
-9,800 Closed
0 $0
Q3 2021

Oct 21, 2021

BUY
$21.26 - $38.85 $208,348 - $380,730
9,800 New
9,800 $289,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Virginia Retirement Systems Et Al Portfolio

Follow Virginia Retirement Systems Et Al and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Virginia Retirement Systems Et Al with notifications on news.